High-affinity IgE receptor (FcεRI) complexed with venom-specific IgE (FcεRI-IgE complex)

The venom-specific IgE bound to the high-affinity IgE receptor (FcεRI) on mast cells and basophils is the primary molecular assembly responsible for Type I hypersensitivity reactions to insect venom (StatPearls: NBK545244). In sensitized individuals, venom-specific IgE antibodies are produced and bind to the FcεRI receptors (UniProt: P12319) located on the surface of effector cells. When the individual is subsequently stung, venom allergens cross-link these receptor-bound IgE molecules, initiating an intracellular signaling cascade that leads to the rapid release of preformed mediators such as histamine and proteases (PubMed: 21854515). This degranulation process is the underlying cause of clinical symptoms ranging from local swelling to systemic anaphylaxis. Therapeutic interventions like venom immunotherapy (VIT) aim to shift the immune response toward IgG4 production or desensitize these cells. Additionally, monoclonal antibodies like omalizumab (PubChem: 160783) can sequester free IgE, preventing its binding to FcεRI and eventually leading to the downregulation of the receptor itself on the cell surface. This complex is a critical target for managing patients at high risk of life-threatening reactions to Hymenoptera stings.

Other names

Fc epsilon RI-IgE complexVenom-specific IgE-FcεRI complexHigh-affinity immunoglobulin E receptor complexIgE-FcεRI signaling complex

Anti-IgE antibodies like omalizumab bind to the Cε3 domain of free IgE, preventing its interaction with the FcεRI receptor (PubChem: 160783). This reduces the density of the IgE-FcεRI complex on mast cells and basophils and inhibits allergen-induced degranulation. Venom immunotherapy (VIT) works by inducing IgG4 blocking antibodies that compete with IgE for allergen binding and by promoting T-cell tolerance (PubMed: 21854515).